低分子量肝素钙联合注射用纤溶酶预防DVT疗效分析

The effect analysis of prevention of deep venous thrombosis about the union of low molecular weight heparin calcium and fibrinogenase

目的：观察低分子肝素钙联合注射用纤溶酶预防下肢深静脉血栓（DVT）形成的临床疗效。方法：122例全髋关节置换术后患者，按照抗凝方法不同分为观察组与对照组，对照组45例，观察组77例。对照组按照常规低分子肝素钙进行治疗，观察组在对照组基础上联合注射用纤溶酶进行治疗。结果：治疗期间，对照组发生DVT4例，观察组无血栓形成，差异有统计学意义（P〈0．05）。此外，观察组患者在纤维蛋白原（Fib）、部分凝血活酶时间（ATPP）、血浆凝血酶原时间（PT）指标改善优于对照组（P〈0．05）。结论：低分子肝素钙联合注射用纤溶酶预防下肢DVT形成具有较好的临床疗效，优于单纯的低分子肝素钙治疗。

objective To observe the clinical effects of Prevention of deep vein thrombosis（DVT）of lower limbs about union of low-molecular-weight heparin and fibrinogenase for Injection after hip replacement surgery.Methods 122 cases of hip replacement patients in our hospital from January 2016 to November were divided into two groups randomly（control group--45 observation group = 77）.The control group was treated only with low molecular heparin calcium,while the observation group was treated with low-molecular-weight heparin and fibrinogenase for injection after surgery.Results 4 cases in control group were come up with DVT while none was happened in observation group.There had significant difference between them（ P 〉 0.05）.In addition,compared with control group,the targets im-provement of fibrinogen,partial thromboplastin time and prothrombin time in the observation group were notable.Conclusion compared with low-molecular-weight heparin,the union of low-molecular-weight heparin and fibrinogenase for injection has better emcacy in preventing DVT.